Congenital hypothalamic hamartoma syndrome

Congenital hypothalamic hamartoma syndrome, also known as Pallister-Hall syndrome (PHS), is a rare genetic disorder characterized by the presence of a hypothalamic hamartoma (a benign tumor-like malformation in the hypothalamus region of the brain) along with a spectrum of additional congenital anomalies. The condition affects multiple body systems, most notably the central nervous system, the skeletal system, and the endocrine system. Key clinical features include hypothalamic hamartoma, which may cause gelastic (laughing) seizures or precocious puberty, polydactyly (extra fingers or toes, often central or postaxial), bifid epiglottis or other airway anomalies, imperforate anus, and pituitary dysfunction that can lead to panhypopituitarism. Some patients may also have renal abnormalities and genital malformations. The severity of Pallister-Hall syndrome is highly variable, ranging from mild forms with polydactyly and a small asymptomatic hamartoma to severe, life-threatening presentations in neonates with large hamartomas, airway compromise, and significant endocrine deficiency. The syndrome is caused by pathogenic variants in the GLI3 gene, which plays a critical role in embryonic development through the Hedgehog signaling pathway. Diagnosis is typically based on clinical findings and confirmed through molecular genetic testing. Treatment is supportive and symptom-directed. Endocrine deficiencies, particularly hypopituitarism, require hormone replacement therapy. Seizures may be managed with antiepileptic medications, and in some cases, surgical intervention for the hypothalamic hamartoma may be considered. Surgical correction may also be needed for imperforate anus, airway anomalies, or significant polydactyly. Prognosis depends on the severity of the malformations, with milder cases having a generally favorable outcome. Genetic counseling is recommended for affected families.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Congenital hypothalamic hamartoma syndrome